microbiome therapeutics Archives

Representative image: Clinical analytics and gastrointestinal imaging scene reflecting Seres Therapeutics’ SER-155 data in checkpoint inhibitor-related enterocolitis and the emerging role of microbiome therapeutics in cancer supportive care.

Why SER-155 could become a key clinical catalyst for Seres Therapeutics

by Venkatesh B
July 10, 2026
0 Comments

Seres Therapeutics Inc. (Nasdaq: MCRB) has reported early clinical data for SER-155 in immune checkpoint inhibitor-related enterocolitis, a gastrointestinal immune-related adverse event that can interrupt cancer immunotherapy. The investigator-sponsored study evaluated the live biotherapeutic in 15 patients with moderate to severe disease and showed an immunosuppressive free clinical response in 80 percent of participants at

Pharma & Biotech

MaaT Pharma AGM strengthens funding authority as MaaT013 faces September regulatory test

by Pallavi Madhiraju
July 7, 2026
0 Comments

MaaT Pharma shareholders have preserved the biotechnology firm’s ability to raise capital as MaaT013 enters a decisive regulatory re-examination and its operating cash runway narrows.

Representative image: Kanvas Biosciences’ Gates Foundation-backed microbiome therapy program highlights how synthetic live biotherapeutics could target maternal environmental enteric dysfunction, a gut disorder linked to undernutrition, low birthweight and newborn health risks in Southern Asia and Sub-Saharan Africa.

Pharma & Biotech

Can Kanvas Biosciences turn microbiome replacement into a maternal health intervention?

by Pallavi Madhiraju
May 10, 2026
0 Comments

Maternal EED lacks scalable therapies. Kanvas Biosciences now faces the harder test: proving microbiome replacement can work where need is greatest.

Pharma & Biotech

Can Vedanta Biosciences turn microbiome therapeutics into a real prevention strategy for recurrent CDI and resistant infections?

by Pallavi Madhiraju
April 12, 2026
0 Comments

Vedanta Biosciences unveiled VE303 and VE707 data at ESCMID 2026. Read why the microbiome strategy matters for CDI and resistant infections.

Representative image of microbiome therapeutics research as Vedanta Biosciences advances VE303 in Phase 3 for recurrent Clostridioides difficile infection, highlighting the growing stakes in standardized live biotherapeutic development.

Pharma & Biotech

Vedanta Biosciences keeps VE303 Phase 3 trial on track as interim review clears futility bar

by Pallavi Madhiraju
April 3, 2026
0 Comments

Vedanta Biosciences kept VE303 Phase 3 on track after interim review. Read what this means for recurrent C. difficile treatment and microbiome drug development.